Inactive Instrument

Evolutionary Genomics, Inc. Stock Other OTC

Equities

FNAM

US30051F1012

Biotechnology & Medical Research

Sales 2021 - Sales 2022 - Capitalization 4.66M
Net income 2021 -2M Net income 2022 -1M EV / Sales 2021 -
Net Debt 2021 3.53M Net Debt 2022 3.17M EV / Sales 2022 -
P/E ratio 2021
-1.34 x
P/E ratio 2022
-2 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 67.35%
More Fundamentals * Assessed data
Dynamic Chart
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding CI
Evolutionary Genomics, Inc. announced that it expects to receive $1.004004 million in funding CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
Managers TitleAgeSince
Founder 69 90-10-31
Chief Executive Officer 68 10-08-31
Members of the board TitleAgeSince
Chief Executive Officer 68 10-08-31
Director/Board Member 64 09-12-31
Founder 74 90-10-31
More insiders
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially traits in crops for the agriculture industry. It uses the Adapted Traits Platform (ATP) to identify commercially valuable genes that control important traits in animals and plants. Its platform identifies genes that have changed successfully to impart new or improved traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The Company uses ATP to perform throughput molecular evolution analysis to identify positively selected genes based on non-synonymous site (Ka) and synonymous site (Ks) analysis.
More about the company